Retrocyclins and their activity against HIV-1

被引:34
|
作者
Penberthy, W. Todd [1 ]
Chari, Soumya [1 ]
Cole, Amy L. [1 ]
Cole, Alexander M. [1 ]
机构
[1] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Dept Mol Biol & Microbiol, Orlando, FL 32816 USA
基金
美国国家卫生研究院;
关键词
Retrocyclin; Defensin; HIV-1; Host defense peptide; Antimicrobial peptide; Antiviral; Microbicide; CELL FUSION INHIBITOR; HERPES-SIMPLEX-VIRUS; ANTIMICROBIAL PEPTIDES; THETA-DEFENSINS; SYNTHETIC PEPTIDE; MARKED INCREASE; TACHYPLESIN; BINDING; RESISTANCE; INFECTION;
D O I
10.1007/s00018-011-0715-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Primate theta-defensins are physically distinguished as the only known fully-cyclic peptides of animal origin. Humans do not produce theta-defensin peptides due to a premature stop codon present in the signal sequence of all six theta-defensin pseudogenes. Instead, since the putative coding regions of human theta-defensin pseudogenes have remained remarkably intact, their corresponding peptides, called "retrocyclins", have been recreated using solid-phase synthetic approaches. Retrocyclins exhibit an exceptional therapeutic index both as inhibitors of HIV-1 entry and as bactericidal agents, which makes retrocyclins promising candidates for further development as topical microbicides to prevent sexually transmitted diseases. This review presents the evolution, antiretroviral mechanism of action, and potential clinical applications of retrocyclins to prevent sexual transmission of HIV-1.
引用
收藏
页码:2231 / 2242
页数:12
相关论文
共 50 条
  • [21] A novel factor produced by placental cells with activity against HIV-1
    Sharma, UK
    Trujillo, J
    Song, HF
    Saitta, FP
    Laeyendecker, OB
    Castillo, R
    Arango-Jaramillo, S
    Sridharan, G
    Dettenhofer, M
    Blakemore, K
    Yu, XF
    Schwartz, DH
    JOURNAL OF IMMUNOLOGY, 1998, 161 (11): : 6406 - 6412
  • [22] IgA antibodies against HIV-1
    Lorin, Valerie
    Mouquet, Hugo
    VIROLOGIE, 2024, 28 (04) : 237 - 253
  • [23] Polynucleotide vaccine against HIV-1
    Moelling, K
    RETROVIRUSES OF HUMAN AIDS AND RELATED ANIMAL DISEASES, 1996, : 303 - 307
  • [24] The Antibody Response against HIV-1
    Overbaugh, Julie
    Morris, Lynn
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2012, 2 (01):
  • [25] Vaccination of chimpanzees against HIV-1
    Girard, M
    BarreSinoussi, F
    vanderRyst, E
    Fultz, P
    DEVELOPMENT AND APPLICATIONS OF VACCINES AND GENE THERAPY IN AIDS, 1996, 48 : 121 - 124
  • [26] ENHANCEMENT OF HIV-1 PROTEINASE ACTIVITY BY HIV-1 REVERSE-TRANSCRIPTASE
    GOOBARLARSSON, L
    LUUKKONEN, BGM
    UNGE, T
    SCHWARTZ, S
    UTTER, G
    STRANDBERG, B
    OBERG, B
    VIROLOGY, 1995, 206 (01) : 387 - 394
  • [27] HIV-1 RT enhances the activity of a tethered dimer of HIV-1 proteinase
    GoobarLarsson, L
    Larsson, PT
    Debouck, C
    Towler, EM
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 220 (01) : 203 - 207
  • [28] Telbivudine Exhibits No Inhibitory Activity against HIV-1 Clinical Isolates In Vitro
    Lin, Kai
    Karwowska, Sylwia
    Lam, Eric
    Limoli, Kay
    Evans, Thomas G.
    Avila, Claudio
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (06) : 2670 - 2673
  • [29] Novel retrocyclin analogs with reduced toxicity and enhanced activity against HIV-1
    Cole, AM
    Cole, AL
    Wang, W
    Jung, G
    Lee, MJ
    Waring, AJ
    Lehrer, RI
    FASEB JOURNAL, 2005, 19 (04): : A373 - A373
  • [30] STRAIN-SPECIFIC CTL ACTIVITY DIRECTED AGAINST HIV-1 ENV
    RAY, SC
    DHRUVA, BR
    SILICIANO, RF
    BOLLINGER, RC
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 225 - 225